BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 24360964)

  • 1. LATS2 suppresses oncogenic Wnt signaling by disrupting β-catenin/BCL9 interaction.
    Li J; Chen X; Ding X; Cheng Y; Zhao B; Lai ZC; Al Hezaimi K; Hakem R; Guan KL; Wang CY
    Cell Rep; 2013 Dec; 5(6):1650-63. PubMed ID: 24360964
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SOX7 Suppresses Wnt Signaling by Disrupting β-Catenin/BCL9 Interaction.
    Fan R; He H; Yao W; Zhu Y; Zhou X; Gui M; Lu J; Xi H; Deng Z; Fan M
    DNA Cell Biol; 2018 Feb; 37(2):126-132. PubMed ID: 29271667
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeted disruption of the BCL9/β-catenin complex inhibits oncogenic Wnt signaling.
    Takada K; Zhu D; Bird GH; Sukhdeo K; Zhao JJ; Mani M; Lemieux M; Carrasco DE; Ryan J; Horst D; Fulciniti M; Munshi NC; Xu W; Kung AL; Shivdasani RA; Walensky LD; Carrasco DR
    Sci Transl Med; 2012 Aug; 4(148):148ra117. PubMed ID: 22914623
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-tumor effect of LATS2 on liver cancer death: Role of DRP1-mediated mitochondrial division and the Wnt/β-catenin pathway.
    Zhang L; Li S; Wang R; Chen C; Ma W; Cai H
    Biomed Pharmacother; 2019 Jun; 114():108825. PubMed ID: 30981110
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The function of BCL9 in Wnt/beta-catenin signaling and colorectal cancer cells.
    de la Roche M; Worm J; Bienz M
    BMC Cancer; 2008 Jul; 8():199. PubMed ID: 18627596
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Sp1/FOXC1/HOTTIP/LATS2/YAP/β-catenin cascade promotes malignant and metastatic progression of osteosarcoma.
    Liu K; Ni JD; Li WZ; Pan BQ; Yang YT; Xia Q; Huang J
    Mol Oncol; 2020 Oct; 14(10):2678-2695. PubMed ID: 32634265
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Tumor-Suppressor WWOX and HDAC3 Inhibit the Transcriptional Activity of the β-Catenin Coactivator BCL9-2 in Breast Cancer Cells.
    El-Hage P; Petitalot A; Monsoro-Burq AH; Maczkowiak F; Driouch K; Formstecher E; Camonis J; Sabbah M; Bièche I; Lidereau R; Lallemand F
    Mol Cancer Res; 2015 May; 13(5):902-12. PubMed ID: 25678599
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel β-catenin/BCL9 complex inhibitor blocks oncogenic Wnt signaling and disrupts cholesterol homeostasis in colorectal cancer.
    Tanton H; Sewastianik T; Seo HS; Remillard D; Pierre RS; Bala P; Aitymbayev D; Dennis P; Adler K; Geffken E; Yeoh Z; Vangos N; Garbicz F; Scott D; Sethi N; Bradner J; Dhe-Paganon S; Carrasco RD
    Sci Adv; 2022 Apr; 8(17):eabm3108. PubMed ID: 35486727
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Wnt status-dependent oncogenic role of BCL9 and BCL9L in hepatocellular carcinoma.
    Huge N; Sandbothe M; Schröder AK; Stalke A; Eilers M; Schäffer V; Schlegelberger B; Illig T; Vajen B; Skawran B
    Hepatol Int; 2020 May; 14(3):373-384. PubMed ID: 31440992
    [TBL] [Abstract][Full Text] [Related]  

  • 10. LINC00689 participates in proliferation, chemoresistance and metastasis via miR-31-5p/YAP/β-catenin axis in colorectal cancer.
    Du YL; Liang Y; Shi GQ; Cao Y; Qiu J; Yuan L; Yong Z; Liu L; Li J
    Exp Cell Res; 2020 Oct; 395(1):112176. PubMed ID: 32682784
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BCL9/9L-β-catenin Signaling is Associated With Poor Outcome in Colorectal Cancer.
    Moor AE; Anderle P; Cantù C; Rodriguez P; Wiedemann N; Baruthio F; Deka J; André S; Valenta T; Moor MB; Győrffy B; Barras D; Delorenzi M; Basler K; Aguet M
    EBioMedicine; 2015 Dec; 2(12):1932-43. PubMed ID: 26844272
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Notch1 counteracts WNT/β-catenin signaling through chromatin modification in colorectal cancer.
    Kim HA; Koo BK; Cho JH; Kim YY; Seong J; Chang HJ; Oh YM; Stange DE; Park JG; Hwang D; Kong YY
    J Clin Invest; 2012 Sep; 122(9):3248-59. PubMed ID: 22863622
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of Novel 3-Phenylpiperidine Derivatives Targeting the β-Catenin/B-Cell Lymphoma 9 Interaction as a Single Agent and in Combination with the Anti-PD-1 Antibody for the Treatment of Colorectal Cancer.
    Zhang H; Liu C; Chen Q; Shen LA; Xiao W; Li J; Wang Y; Zhu D; Zhang Q; Li J
    J Med Chem; 2023 Jan; 66(2):1349-1379. PubMed ID: 36630177
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A coactivator role of CARM1 in the dysregulation of β-catenin activity in colorectal cancer cell growth and gene expression.
    Ou CY; LaBonte MJ; Manegold PC; So AY; Ianculescu I; Gerke DS; Yamamoto KR; Ladner RD; Kahn M; Kim JH; Stallcup MR
    Mol Cancer Res; 2011 May; 9(5):660-70. PubMed ID: 21478268
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dickkopf-Related Protein 2 is Epigenetically Inactivated and Suppresses Colorectal Cancer Growth and Tumor Metastasis by Antagonizing Wnt/β-Catenin Signaling.
    Wang C; Yue Y; Shao B; Qiu Z; Mu J; Tang J; Han X; Xiang T; Ren G
    Cell Physiol Biochem; 2017; 41(5):1709-1724. PubMed ID: 28365691
    [TBL] [Abstract][Full Text] [Related]  

  • 16. β-catenin inhibits promyelocytic leukemia protein tumor suppressor function in colorectal cancer cells.
    Satow R; Shitashige M; Jigami T; Fukami K; Honda K; Kitabayashi I; Yamada T
    Gastroenterology; 2012 Mar; 142(3):572-81. PubMed ID: 22155184
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BCL9-2 promotes early stages of intestinal tumor progression.
    Brembeck FH; Wiese M; Zatula N; Grigoryan T; Dai Y; Fritzmann J; Birchmeier W
    Gastroenterology; 2011 Oct; 141(4):1359-70, 1370.e1-3. PubMed ID: 21703997
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The interactions of Bcl9/Bcl9L with β-catenin and Pygopus promote breast cancer growth, invasion, and metastasis.
    Vafaizadeh V; Buechel D; Rubinstein N; Kalathur RKR; Bazzani L; Saxena M; Valenta T; Hausmann G; Cantù C; Basler K; Christofori G
    Oncogene; 2021 Oct; 40(43):6195-6209. PubMed ID: 34545187
    [TBL] [Abstract][Full Text] [Related]  

  • 19. hSETD1A regulates Wnt target genes and controls tumor growth of colorectal cancer cells.
    Salz T; Li G; Kaye F; Zhou L; Qiu Y; Huang S
    Cancer Res; 2014 Feb; 74(3):775-86. PubMed ID: 24247718
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of a BCL9-related beta-catenin-binding protein, B9L, in tumorigenesis induced by aberrant activation of Wnt signaling.
    Adachi S; Jigami T; Yasui T; Nakano T; Ohwada S; Omori Y; Sugano S; Ohkawara B; Shibuya H; Nakamura T; Akiyama T
    Cancer Res; 2004 Dec; 64(23):8496-501. PubMed ID: 15574752
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.